ImmunoGen, Inc. (Nasdaq: IMGN) released news that its experimental therapy for breast cancer achieved positive phase 2 trial results. The results showed that new ImmunoGen’s therapy could potentially be more effective than a combination of Herceptin and chemotherapy, which is the current standard of care for many HER2-positive breast cancer patients.
IMGN surged on this news & rumor of the potential buyout. So far IMGN offered excellent daytrading opportunity: